

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. **(Previously presented)** An inhalable powder pharmaceutical composition comprising:
  - (a) a tiotropium salt;
  - (b) a steroid, and
  - (c) a pharmaceutically acceptable excipient selected from the group consisting of glucose, arabinose, lactose, saccharose, and maltosewherein the tiotropium salt and the steroid are optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates.
2. **(Cancelled)**
3. **(Previously presented)** The inhalable powder pharmaceutical composition according to claim 1, wherein the tiotropium salt is tiotropium chloride, tiotropium bromide, tiotropium iodide, tiotropium *p*-toluene sulfonate, or tiotropium methylsulfate.
4. **(Previously presented)** The inhalable powder pharmaceutical composition of claim 3, wherein the tiotropium salt is tiotropium bromide.
5. **(Previously presented)** The inhalable powder pharmaceutical composition according to claim 1, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW 215864, KSR 592, ST-126, and dexamethasone.
6. **(Currently Amended)** The inhalable powder pharmaceutical composition according to claim 1, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, ~~triamcinolone~~, budesonide, and fluticasone, ~~mometasone~~, ~~ciclesonide~~,

rofleponide, GW 215864, KSR 592, ST-126, and dexamethasone.

**7. (Previously presented)** The inhalable powder pharmaceutical composition according to claim 3, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW 215864, KSR 592, ST-126, and dexamethasone.

**8. (Previously presented)** The inhalable powder pharmaceutical composition according to claim 3, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, and dexamethasone.

**9. (Previously presented)** The inhalable powder pharmaceutical composition according to claim 1, wherein the weight ratios of the anticholinergic to the steroid are in the range of from 1:300 to 50:1.

**10. (Previously presented)** The inhalable powder pharmaceutical composition according to claim 7, wherein the weight ratios of the tiotropium salt to the steroid are in the range of from 1:250 to 40:1.

**11. – 14. (Cancelled)**

**15. (Previously presented)** The inhalable powder pharmaceutical composition of claim 1, wherein the excipient has a maximum average particle size of up to 250  $\mu\text{m}$ .

**16. (Previously presented)** The inhalable powder pharmaceutical composition of claim 3, wherein the excipient has a maximum average particle size of up to 250  $\mu\text{m}$ .

**17. (Previously presented)** The inhalable powder pharmaceutical composition of claim 4, wherein the excipient has a maximum average particle size of up to 250  $\mu\text{m}$ .

**18. (Previously presented)** The inhalable powder pharmaceutical composition of claim 5, wherein the excipient has a maximum average particle size of up to 250  $\mu\text{m}$ .

**19. (Previously presented)** The inhalable powder pharmaceutical composition of claim 15, wherein the excipient has a maximum average particle size of between 10  $\mu\text{m}$  and 150  $\mu\text{m}$ .

**20. (Previously presented)** The inhalable powder pharmaceutical composition of claim 16, wherein the excipient has a maximum average particle size of between 10  $\mu\text{m}$  and 150  $\mu\text{m}$ .

**21. (Previously presented)** The inhalable powder pharmaceutical composition of claim 17, wherein the excipient has a maximum average particle size of between 10  $\mu\text{m}$  and 150  $\mu\text{m}$ .

**22. (Previously presented)** The inhalable powder pharmaceutical composition of claim 18, wherein the excipient has a maximum average particle size of between 10  $\mu\text{m}$  and 150  $\mu\text{m}$ .

**23. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 1.

**24. (Canceled)**

**25. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 3.

**26. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 4.

**27. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 5.

**28. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 6.

**29. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 7.

**30. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 8.

**31. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 9.

**32. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 10.

**33. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 19.

**34. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 20.

**35. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 15.

**36. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 16.

**37. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 17.

**38. (Previously presented)** A capsule containing the inhalable powder pharmaceutical composition according to claim 18.

**39. (Previously presented)** A pharmaceutical composition consisting essentially of:

- (a) tiotropium salt; and
- (b) a steroid,

wherein the pharmaceutical composition is in the form of an inhalable powder.

**40. – 62. (Cancelled)**

**63. (Currently Amended)** A kit comprising one or more unit dosage containers containing a an inhalable powder pharmaceutical composition comprising:

- (a) a tiotropium salt;
- (b) a steroid, and

a pharmaceutically acceptable excipient selected from the group consisting of glucose, arabinose, lactose, saccharose, and maltose, tiotropium salt and the steroid optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates.

**64. (Original)** The kit according to claim 63, further comprising instructions with directions for using the kit.

**65. (Currently Amended)** A kit comprising:

- (a) a first container containing a first inhalable powder pharmaceutical formulation comprising a tiotropium salt and;
- (b) a second container containing a second inhalable powder pharmaceutical formulation comprising a steroid,

each container further containing a pharmaceutically acceptable excipient selected from the group consisting of glucose, arabinose, lactose, saccharose, and maltose.

**66. (Original)** The kit according to claim 65, further comprising instructions with directions for using the kit.